Evidence map›Paper›PMID 35127397›Full record

ArticleActa pharmaceutica Sinica. B2022

A real-time and modular approach for quick detection and mechanism exploration of DPIs with different carrier particle sizes.

Yingtong Cui, Ying Huang, Xuejuan Zhang, Xiangyun Lu, Jun Xue, Guanlin Wang, Ping Hu, Xiao Yue, Ziyu Zhao, Xin Pan and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.Journal of aerosol medicine and pulmonary drug delivery · 2024
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yingtong CuiSchool of Pharmaceutical Science, Jinan University, Guangzhou 510006, China.
Ying HuangSchool of Pharmaceutical Science, Jinan University, Guangzhou 510006, China.
Xuejuan ZhangSchool of Pharmaceutical Science, Jinan University, Guangzhou 510006, China.
Xiangyun LuMicromeritics Instrument (Shanghai) Ltd., Shanghai 200135, China.
Jun XueMEGGLE Group Shanghai Representative Office, Shanghai 201315, China.
Guanlin WangSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Ping HuSchool of Pharmaceutical Science, Jinan University, Guangzhou 510006, China.
Xiao YueSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Ziyu ZhaoSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Xin PanSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Chuanbin WuSchool of Pharmaceutical Science, Jinan University, Guangzhou 510006, China.
Sun Yat-sen University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dry powder inhalers (DPIs) had been widely used in lung diseases on account of direct pulmonary delivery, good drug stability and satisfactory patient compliance. However, an indistinct understanding of pulmonary delivery processes (PDPs) hindered the development of DPIs. Most current evaluation methods explored the PDPs with over-simplified models, leading to uncompleted investigations of the whole or partial PDPs. In the present research, an innovative modular process analysis platform (MPAP) was applied to investigate the detailed mechanisms of each PDP of DPIs with different carrier particle sizes (CPS). The MPAP was composed of a laser particle size analyzer, an inhaler device, an artificial throat and a pre-separator, to investigate the fluidization and dispersion, transportation, detachment and deposition process of DPIs. The release profiles of drug, drug aggregation and carrier were monitored in real-time. The influence of CPS on PDPs and corresponding mechanisms were explored. The powder properties of the carriers were investigated by the optical profiler and Freeman Technology four powder rheometer. The next generation impactor was employed to explore the aerosolization performance of DPIs. The novel MPAP was successfully applied in exploring the comprehensive mechanism of PDPs, which had enormous potential to be used to investigate and develop DPIs.

Indexed as

AE, aerated energyAPIs, active pharmaceutical ingredientsAR, aeration ratioBFE, basic flow EnergyCarrier particle sizeCFD-DEM, computational fluid dynamics-discrete element methodC.OPT, optical concentrationCPS, carrier particle sizedae, aerodynamic diameterDPIs, dry powder inhalersdQ3, the volume percentage of particles within certain rangeDry powder inhalerED, emitted doseEDXS, energy-dispersive X-ray spectroscopyFC, centrifugal forceFD, drag forceFF, friction forceFG, gravityFI, interaction forceFPD, fine particle doseFPF, fine particle fractionFP, press-on forceFT4, Freeman Technology 4HPLC, high performance liquid chromatographyHPMC, hydroxypropyl methyl celluloseLAC, lactoseMFV, minimum fluidization velocityMMAD, mass median aerodynamic diameterMOC, micro orifice collectorMPAP, modular process analysis platformMSS, micronized salbutamol sulfateNGI, Next Generation ImpactorO, oxygenPDP, pulmonary delivery processPD, pressure dropPSF, particle size fractionsPulmonary delivery processQuick detectionRAUC, total release amountReal-time monitorRmax, maximum of release amountR, release amountSEM, scanning electron microscopeSE, specific energySSA, specific surface areaS, stopping distanceTE, total engeryTmax, the time to reach RmaxT, timeTt, terminal timeU0, air flow rateV0, velocity

Identifiers

PMID35127397
PMCPMC8799997
OpenAlexW3173227803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.